Literature DB >> 21039469

Natural killer cells in human autoimmune diseases.

Nicolas Schleinitz1, Frédéric Vély, Jean-Robert Harlé, Eric Vivier.   

Abstract

Natural killer (NK) cells have been implicated in tumour surveillance and in the early control of several microbial infections. In autoimmune disease their involvement in these processes has been evaluated in animal models, with conflicting results. Both a disease-controlling and a disease-promoting role have been suggested. In human autoimmune disease only a few studies, mainly descriptive, have demonstrated qualitative and quantitative modification of NK cells. These changes were observed on blood- or tissue-infiltrating NK cells. Taken together with our expanding knowledge of the genetical variability of NK cell receptors and NK cell physiology, these findings pave the way for the dissection of the role of NK cells in human autoimmune diseases. NK cells may be directly involved in these diseases through their potential autoreactivity or through their interaction with dendritic cells, macrophages or T lymphocytes, thereby inducing excessive inflammation or favouring the adaptive autoimmune response. Thus, NK cells may be implicated in the onset, the maintenance or the progression of autoimmune diseases. Some reports also suggest the involvement of NK cells in the treatment of human autoimmune disease by biotherapies. All these observations suggest that NK cells are involved in the complex processes of autoimmune diseases. Nevertheless, further careful analysis of NK cells at different steps of these diseases, in different tissues and through combined genetical and functional studies will contribute to a better understanding of their role in autoimmune diseases. This knowledge might allow the development of new therapeutic strategies based on NK cells for the treatment of some autoimmune diseases.
© 2010 The Authors. Immunology © 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21039469      PMCID: PMC2999796          DOI: 10.1111/j.1365-2567.2010.03360.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  56 in total

1.  Regulatory NK cells suppress antigen-specific T cell responses.

Authors:  Gunnur Deniz; Gaye Erten; Umut Can Kücüksezer; Dilara Kocacik; Christian Karagiannidis; Esin Aktas; Cezmi A Akdis; Mubeccel Akdis
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

2.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.

Authors:  Todd A Fehniger; Megan A Cooper; Gerard J Nuovo; Marina Cella; Fabio Facchetti; Marco Colonna; Michael A Caligiuri
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

Review 4.  The biology of human natural killer-cell subsets.

Authors:  M A Cooper; T A Fehniger; M A Caligiuri
Journal:  Trends Immunol       Date:  2001-11       Impact factor: 16.687

5.  Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules.

Authors:  H T Moins-Teisserenc; S D Gadola; M Cella; P R Dunbar; A Exley; N Blake; C Baykal; J Lambert; P Bigliardi; M Willemsen; M Jones; S Buechner; M Colonna; W L Gross; V Cerundolo; C Baycal
Journal:  Lancet       Date:  1999-11-06       Impact factor: 79.321

6.  The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors.

Authors:  Mariella Della Chiesa; Massimo Vitale; Simona Carlomagno; Guido Ferlazzo; Lorenzo Moretta; Alessandro Moretta
Journal:  Eur J Immunol       Date:  2003-06       Impact factor: 5.532

Review 7.  Clinical features of large granular lymphocyte leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Semin Hematol       Date:  2003-07       Impact factor: 3.851

8.  Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes.

Authors:  Renato Zambello; Michela Falco; Mariella Della Chiesa; Livio Trentin; Davide Carollo; Roberta Castriconi; Giovanna Cannas; Simona Carlomagno; Anna Cabrelle; Thierry Lamy; Carlo Agostini; Alessandro Moretta; Gianpietro Semenzato; Massimo Vitale
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

9.  Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles.

Authors:  Maureen P Martin; George Nelson; Jeong-Hee Lee; Fawnda Pellett; Xiaojiang Gao; Judith Wade; Michael J Wilson; John Trowsdale; Dafna Gladman; Mary Carrington
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

10.  A subset of natural killer cells is greatly expanded within inflamed joints.

Authors:  Nicola Dalbeth; Margaret F C Callan
Journal:  Arthritis Rheum       Date:  2002-07
View more
  69 in total

Review 1.  Natural killer cell tolerance: control by self or self-control?

Authors:  Baptiste N Jaeger; Eric Vivier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-03-01       Impact factor: 10.005

Review 2.  Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.

Authors:  Martha Luevano; Alejandro Madrigal; Aurore Saudemont
Journal:  Cell Mol Immunol       Date:  2012-06-18       Impact factor: 11.530

3.  Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation.

Authors:  Qiang Liu; Nader Sanai; Wei-Na Jin; Antonio La Cava; Luc Van Kaer; Fu-Dong Shi
Journal:  Nat Neurosci       Date:  2016-01-11       Impact factor: 24.884

4.  HIV and decreased risk of multiple sclerosis: role of low CD4+ lymphocyte count and male prevalence.

Authors:  Tatiana Koudriavtseva; Domenico Plantone; Chiara Mandoj; Diana Giannarelli; Alessandra Latini; Manuela Colafigli; Elisabetta Trento; Paola Cordiali-Fei; Fulvia Pimpinelli
Journal:  J Neurovirol       Date:  2016-07-18       Impact factor: 2.643

5.  Dysregulation of TLR9 in neonates leads to fatal inflammatory disease driven by IFN-γ.

Authors:  Alison G Stanbery; Zachary R Newman; Gregory M Barton
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-24       Impact factor: 11.205

Review 6.  Targeting natural killer cells and natural killer T cells in cancer.

Authors:  Eric Vivier; Sophie Ugolini; Didier Blaise; Christian Chabannon; Laurent Brossay
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 7.  What rheumatologists need to know about innate lymphocytes.

Authors:  Mark A Exley; George C Tsokos; Kingston H G Mills; Dirk Elewaut; Ben Mulhearn
Journal:  Nat Rev Rheumatol       Date:  2016-09-02       Impact factor: 20.543

8.  Decreased A20 expression on circulating CD56bright NK cells contributes to a worse disease status in patients with ankylosing spondylitis.

Authors:  M Yang; Y Zhou; L Liu; S Wang; J Jiang; Q Shang; H Yu; X Xiang; X Pang; T Li; P Zhao
Journal:  Clin Exp Immunol       Date:  2019-06-30       Impact factor: 4.330

9.  Human NKG2E is expressed and forms an intracytoplasmic complex with CD94 and DAP12.

Authors:  Gerasim A Orbelyan; Fangming Tang; Benjamin Sally; Jason Solus; Bertrand Meresse; Cezary Ciszewski; Jean-Christophe Grenier; Luis B Barreiro; Lewis L Lanier; Bana Jabri
Journal:  J Immunol       Date:  2014-06-16       Impact factor: 5.422

10.  Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma.

Authors:  Cindy Barnig; Manuela Cernadas; Stefanie Dutile; Xiaoli Liu; Mark A Perrella; Shamsah Kazani; Michael E Wechsler; Elliot Israel; Bruce D Levy
Journal:  Sci Transl Med       Date:  2013-02-27       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.